Cosmo Pharmaceuticals NV (COPN):企業の財務・戦略的SWOT分析

◆英語タイトル:Cosmo Pharmaceuticals NV (COPN) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH63441FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アイルランド
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥64,800見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥97,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cosmo Pharmaceuticals NV (Cosmo) is a pharmaceutical company that develops drugs for the treatment of gastro-intestinal diseases. The company develops its pharmaceutical products based on its multi matrix technology. Its proprietary clinical development pipeline intended for the treatment of various gastro-intestinal tract, inflammatory bowel diseases, colon infections and colon diagnosis. Cosmo also provides Eleview, a submucosal injectable composition for extracting polyps and adenomas; and other products. It offers products under Lialda, Uceris, Gi Genius, and Cortiment brands. The company manufactures products for oral administration, topical dosage forms such as emulsions, ointments and injectables. Its manufacturing facility is located in Lainate, Milan. Cosmo is headquartered in Dublin, Ireland.

Cosmo Pharmaceuticals NV Key Recent Developments

Mar 19,2021: Cosmo Pharmaceuticals 2020 results and 2021 outlook presentation conference call on 26 March 2021
Feb 18,2021: 07:00 ET RedHill Biopharma Strengthens Partnership with Cosmo Pharmaceuticals with Manufacturing Agreements for Movantik and RHB-204 RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced
Dec 01,2020: Cosmo Pharmaceuticals appoints new Chief Medical Officer
Jul 30,2020: Cosmo Half-Year Report 2020

This comprehensive SWOT profile of Cosmo Pharmaceuticals NV provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Cosmo Pharmaceuticals NV including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Cosmo Pharmaceuticals NV – Key Information
Cosmo Pharmaceuticals NV – Overview
Cosmo Pharmaceuticals NV – Key Employees
Cosmo Pharmaceuticals NV – Key Employee Biographies
Cosmo Pharmaceuticals NV – Key Operational Heads
Cosmo Pharmaceuticals NV – Major Products and Services
Cosmo Pharmaceuticals NV – History
Cosmo Pharmaceuticals NV – Company Statement
Cosmo Pharmaceuticals NV – Locations And Subsidiaries
Cosmo Pharmaceuticals NV
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Cosmo Pharmaceuticals NV – Business Description
Cosmo Pharmaceuticals NV – Corporate Strategy
Cosmo Pharmaceuticals NV – SWOT Analysis
SWOT Analysis – Overview
Cosmo Pharmaceuticals NV – Strengths
Cosmo Pharmaceuticals NV – Weaknesses
Cosmo Pharmaceuticals NV – Opportunities
Cosmo Pharmaceuticals NV – Threats
Cosmo Pharmaceuticals NV – Key Competitors

Section 3 – Company Financial Performance Charts

Cosmo Pharmaceuticals NV – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Cosmo Pharmaceuticals NV, Key Information
Cosmo Pharmaceuticals NV, Key Ratios
Cosmo Pharmaceuticals NV, Share Data
Cosmo Pharmaceuticals NV, Major Products and Services
Cosmo Pharmaceuticals NV, History
Cosmo Pharmaceuticals NV, Key Employees
Cosmo Pharmaceuticals NV, Key Employee Biographies
Cosmo Pharmaceuticals NV, Key Operational Heads
Cosmo Pharmaceuticals NV, Other Locations
Cosmo Pharmaceuticals NV, Subsidiaries
Cosmo Pharmaceuticals NV, Key Competitors
Cosmo Pharmaceuticals NV, SWOT Analysis
Cosmo Pharmaceuticals NV, Ratios based on current share price
Cosmo Pharmaceuticals NV, Annual Ratios
Cosmo Pharmaceuticals NV, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Cosmo Pharmaceuticals NV (COPN):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Gemini Corp (GKX)-石油・ガス分野:企業M&A・提携分析
    Summary Gemini Corporation (Gemini) is an oil and gas engineering company that provides engineering, field and environmental solutions. The company offers services including project management systems, fabrication, maintenance, procurement, construction, land, environmental, regulatory, and reclamat …
  • Jcb Co., Ltd.:企業の戦略・SWOT・財務分析
    Jcb Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Jcb Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Centrica Plc Oil & Gas Exploration and Production Operations and Cost Analysis – 2017
    Centrica Plc Oil & Gas Exploration and Production Operations and Cost Analysis - 2017 Summary Centrica Plc (Centrica) is an integrated energy company. It carries out electricity generation through and combined cycle gas turbine (CCGT) power stations, and nuclear power plants through its stake in EDF …
  • Rothschild Bank Ag:企業の戦略・SWOT・財務分析
    Rothschild Bank Ag - Strategy, SWOT and Corporate Finance Report Summary Rothschild Bank Ag - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Juntendo University:製薬・医療:M&Aディール及び事業提携情報
    Summary Juntendo University (Juntendo) is a healthcare service provider that offers medical education and research programs and services. The university offers services such as medical education, practices and healthcare services including nursing, consultation, emergency room services, and others. …
  • Arsenal Medical Inc:医療機器:M&Aディール及び事業提携情報
    Summary Arsenal Medical Inc (Arsenal) is a platform technology company that develops novel therapeutic polymer based foams. The company’s products include in-situ forming materials, in-situ forming polymeric foam and in-situ curing elastomeric polymer material. It offers in-situ forming materials to …
  • Sodra Skogsagarna ekonomisk forening:企業の戦略的SWOT分析
    Sodra Skogsagarna ekonomisk forening - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • Wellcome Trust Sanger Institute:製薬・医療:M&Aディール及び事業提携情報
    Summary Wellcome Trust Sanger Institute (Sanger Institute) a subsidiary of Genome Research Ltd is a genomic discovery and research centre that carries out research and development in the areas of cellular and human genetics and infection genomics. It also provides postgraduate training on research a …
  • UCB Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary UCB Inc (UCB), a subsidiary of UCB SA, is a healthcare solutions provider that offers therapeutics. The company develops products with an emphasis on central nervous system and immunology therapeutic domains. Its products include cimzia, vimpat, keppra XR, neupro, tussionex pennkinetic, meta …
  • CiMaas BV:製薬・医療:M&Aディール及び事業提携情報
    Summary CiMaas BV (CiMaas) develops cellular immunotherapies (vaccines) for the treatment of cancer. Its pipeline cellular therapeutic products include CIM101, a dendritic cell vaccine being developed using its proprietary maturation technology for the treatment of lung cancer; and CIM201, a haploid …
  • H. Lundbeck AS (LUN):企業の財務・戦略的SWOT分析
    H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Expedia Inc:戦略・SWOT・企業財務分析
    Expedia Inc - Strategy, SWOT and Corporate Finance Report Summary Expedia Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Tianjin Zhongxin Pharmaceutical Group Corp Ltd (600329)-製薬・医療分野:企業M&A・提携分析
    Summary Tianjin Zhongxin Pharmaceutical Group Corp Ltd (TZPG) manufactures and markets traditional Chinese medicine, western medicine and health products. The company offers Chinese patent medicines, Chinese medicinal materials, western medicines, dietary supplements, pharmaceutical raw materials an …
  • Axonics Modulation Technologies Inc (AXNX):医療機器:M&Aディール及び事業提携情報
    Summary Axonics Modulation Technologies Inc (Axonics) is an independent medical device company that develops and commercializes implantable neuromodulation technology for the treatment of urinary and bowel dysfunction. The company’s Sacral Neuromodulation System (r-SNM) is designed for the treatment …
  • Vancouver City Savings Credit Union:企業の戦略・SWOT・財務情報
    Vancouver City Savings Credit Union - Strategy, SWOT and Corporate Finance Report Summary Vancouver City Savings Credit Union - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Altern Energy Ltd (ALTN):企業の財務・戦略的SWOT分析
    Altern Energy Ltd (ALTN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Velocys Plc (VLS):企業の財務・戦略的SWOT分析
    Velocys Plc (VLS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • National Institute of Neurological Disorders and Stroke-製薬・医療分野:企業M&A・提携分析
    Summary National Institute of Neurological Disorders and Stroke (NINDS), a subsidiary of National Institutes of Health is a healthcare research institute that conducts and supports research on brain and nervous system disorders. The institute’s clinical research areas include Alzheimer’s disease, br …
  • Shikoku Electric Power Co., Inc.:企業の戦略・SWOT・財務分析
    Shikoku Electric Power Co., Inc. - Strategy, SWOT and Corporate Finance Report Summary Shikoku Electric Power Co., Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • MWH Global Inc:企業の戦略的SWOT分析
    MWH Global Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆